Funder
This article is published under the Creative Commons Attribution Noncommercial License.
Publisher
Touch Medical Media, Ltd.
Reference9 articles.
1. Ghielmini M, Vitolo U, Kimby E, et al. ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL).Ann Oncol. 2013;24:561–76.
2. Gisselbrecht C, Van Den Neste E. How I manage patients with relapsed/refractory diffuse large B cell lymphoma.Br J Haematol. 2018;182:633–43.
3. Shustik C, Bence-Bruckler I, Delage R, et al. Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia.Ann Hematol. 2017;96:1185–96.
4. MacDonald D, Prica A, Assouline S, et al. Emerging therapies for the treatment of relapsed or refractory follicular lymphoma.Curr Oncol. 2016;23:407–17.
5. Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia.N Engl J Med. 2018;378:1107–20.